Henagliflozin - Jiangsu HengRui MedicineAlternative Names: SHR-3824
Latest Information Update: 28 Jul 2018
Price : *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihyperglycaemics; Glucosides
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In the elderly, In adults) in China (PO, Tablet)
- 01 Nov 2017 Jiangsu HengRui Medicine plans a phase I drug interaction trial for Type 2 diabetes mellitus (In volunteers) (PO) (NCT03329118)
- 22 May 2017 Jiangsu HengRui Medicine plans a phase III trial for Type-2 diabetes mellitus (Monotherapy) in China (NCT03159052)